Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Overall Survival
Inclusion criteria
- To evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotibib 150 mg once a day in subjects with unresectable advanced or metastatic Child-Pugh A HCC